New Technology– category –
-
TSMC Doubles Advanced Packaging Capacity Over Three Years; Samsung Expands 2nm & Advanced Packaging Collaboration with Broadcom
BigGo Finance Taiwan Overview TSMC revealed it has doubled its advanced packaging capacity annually for the past three years but still lags behind surging AI chip demand, operating 10 dedicated facilities globally. Meanwhile, Samsung Ele... -
Samsung Unveils zHBM, a 3D Logic-Memory Integrated AI Architecture, Alongside HBM4E/HBM5 Roadmap at FMS 2026
Samsung Semiconductor South Korea Overview Samsung presented its vision for next-generation AI infrastructure at FMS 2026, unveiling its HBM roadmap, including HBM4E and HBM5, and a novel 3D memory architecture called zHBM. This zHBM sol... -
JEDEC Relaxes HBM4 Package Height to 775 µm, Enabling 12-Hi/16-Hi Stacks Without Immediate Cu-Cu Hybrid Bonding
Exponential Industry USA Overview JEDEC has relaxed the HBM4 package height specification from 720 µm to 775 µm, allowing for 12-Hi and 16-Hi stack HBM modules without immediate reliance on Cu-Cu hybrid bonding. HBM utilizes 3D stacked D... -
NVIDIA Accelerates Feynman AI Platform; TSMC Ramps SoIC Capacity to 50K Wafers/Month by 2027
Benzinga Taiwan Overview NVIDIA is expediting the roadmap for its next-generation Feynman AI platform, prompting TSMC to significantly boost its advanced packaging capabilities. TSMC is rapidly expanding its SoIC technology production, a... -
Xcellon Biologics Acquires NextCure GMP Facility, Establishes End-to-End CRDMO for Next-Gen Bioconjugates, Streamlining Development from Discovery to Clinical Supply
Outsourced Pharma USA Overview Xcellon Biologics has acquired a GMP manufacturing facility from NextCure, transforming into an end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) for next-generation bioconju... -
ProQR Therapeutics Marks Landmark: Axiomer RNA Editing Platform Achieves First Clinical Validation for Cholestatic Liver Disease Therapy
Quartr Sweden Overview ProQR Therapeutics has reported the first clinical validation of its proprietary Axiomer RNA editing platform, achieved through Phase 1 target engagement data for AX-0810. This candidate demonstrated modulation of ... -
Rice University Engineers Harness Electrostatic Charge for Weeks-Long Controlled Peptide Release, Revolutionizing Regenerative Medicine
Rice University USA Overview Engineers at Rice University have developed a novel strategy to precisely control the release of therapeutic peptides from gelatin-based materials. By adjusting the peptide's electrical charge, the team signi... -
Beijing Designates Xtalpi and Gan & Lee’s AI Peptide Delivery Lab as Key National Facility for Oral Drug Innovation
Insight, China's Pharmaceutical Industry China Overview The AI Peptide Delivery Lab, a joint venture by Xtalpi and Gan & Lee Pharmaceuticals, has been officially designated a Beijing Key Laboratory, recognizing its cutting-edge R&... -
FDA Grants Dual Breakthrough and Orphan Designations to Volixibat for PSC-Related Cholestatic Pruritus
HCPLive USA Overview The U.S. FDA has granted both Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) to volixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, for the treatment of cholestatic p... -
Monte Rosa’s AI-Powered Molecular Glue Degrader MRT-6160 Achieves >90% VAV1 Degradation and Potent Cytokine Suppression in Phase 1, Prompting Multiple Novartis-Led Phase 2 Trials
Quartr Sweden Overview Monte Rosa Therapeutics has announced that its AI-driven QuEEN platform's molecular glue degrader (MGD) MRT-6160 achieved over 90% VAV1 protein degradation and potent cytokine suppression in Phase 1 trials. This su...
